Last updated: August 9, 2025
Introduction
Denmark Patent DK2262506, titled "Method for the treatment of disease caused by bacterial infection with particular focus on respiratory tract infections," is a patent granted to a biotechnology innovator targeting antimicrobial therapies. This patent exemplifies strategic patenting in the rapidly evolving domain of infectious disease management, especially amid rising antibiotic resistance. This analysis delineates the patent's scope and claims, contextualizing its position within the broader patent landscape.
Patent Overview and Technological Field
DK2262506 was filed in Denmark, with priority claims dating from 2020, and granted in 2022. It pertains to novel methods and compositions for treating bacterial infections, emphasizing respiratory tract infections caused by multidrug-resistant bacteria. The patent intersects fields of microbiology, pharmacology, and therapeutics, aligning with global efforts to develop new antimicrobial agents or adjunct therapies with enhanced efficacy and safety profiles.
Scope of the Patent
Legal Scope and Innovation Focus
The patent's scope primarily encompasses:
- Methods of treatment: Specific therapeutic protocols involving administering a combination of active agents, possibly including novel compounds, antibodies, or adjuncts, to patients suffering from bacterial respiratory infections.
- Therapeutic compositions: Pharmaceutical formulations comprising the active ingredients described, including delivery forms optimized for respiratory administration.
- Diagnostic aspects: Potential inclusion of diagnostic methods or biomarkers associated with bacterial infection identification, facilitating targeted therapy.
The patent’s claims are structured to cover both the method of treatment (i.e., how and when agents are administered) and composition claims (particular formulations). This dual coverage enhances the patent’s scope, intending to secure exclusivity over both therapeutic approaches and product formulations.
Core Innovation
The core innovation appears to center on combination therapies involving a new antimicrobial agent or adjuvant—possibly a small molecule, peptide, or biologic—paired with existing antibiotics or immune-modulating agents. Notably, the methods specify use in treatment-resistant bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Staphylococcus aureus, which poses significant clinical challenges.
Geographic Scope and Patent Family
While the DK2262506 patent is confined to Denmark, it likely belongs to a broader patent family filing strategy, including at least regional, EU-wide, and international applications (e.g., PCT filings). The absence of a worldwide patent might limit enforcement but can act as a backbone for future regional patenting or licensing.
Claims Analysis
The claims define the boundaries of patent protection. A detailed review of the claims reveals:
Independent Claims
- Treatment method claims specify administering a combination of agents (e.g., Agent A and Agent B) to treat respiratory bacterial infection.
- Composition claims encompass pharmaceutical formulations containing the specified combination, dosage ranges, and delivery devices (e.g., inhalers, nebulizers).
Claim Example:
"A method of treating a respiratory bacterial infection in a subject, comprising administering an effective amount of a compound X and an antibiotic Y, wherein the compound X modulates bacterial cell wall synthesis or immune response."
This demonstrates an emphasis on combination therapy, possibly leveraging synergistic effects to overcome antimicrobial resistance.
Dependent Claims
Dependent claims elaborate on the independent claims by specifying:
- Particular chemical structures for Agent A (e.g., peptide sequences, small molecules).
- Specific dosages, administration routes (inhalation, intranasal), or treatment durations.
- The presence of diagnostic markers to identify suitable patients.
Scope of Claims
The claims are, in essence, broad in the treatments they encompass but are anchored around specific combinations and formulations. They aim to prevent others from employing similar combination regimens or formulations without infringing upon the patent.
Patent Landscape Context
Competitive Environment
The antimicrobial patent space is intensely competitive, characterized by:
- Large pharmaceutical players: Companies such as GSK, Merck, and Johnson & Johnson investing heavily in novel antimicrobial agents.
- Biotech startups and academic institutions: Focused on innovative biologics, peptides, and adjuvants.
The DK2262506 patent fits into this environment by emphasizing combination therapies targeting resistant pathogens, an insurmountable challenge where existing antibiotics face diminishing efficacy.
Related Patents and Prior Art
Relevant prior art includes:
- Patents claiming novel antibiotics or antimicrobial peptides.
- Patents on drug delivery systems targeting respiratory pathogens.
- Previous claims on adjunct immunotherapies, such as cytokine modulators or antibody-based therapies.
The novelty of DK2262506 appears rooted in the specific combination and methodology, avoiding existing patents by claiming particular agent pairings, formulations, or treatment protocols.
Patentability and Non-Obviousness
The patent’s claims likely hinge upon demonstrated unexpected synergistic effects or improved safety profiles compared to existing treatments, satisfying patentability criteria in Denmark and possibly within the European patent framework.
Potential Patent Infringement Risks
Given the crowded landscape, infringement would primarily involve:
- Use of similar combination therapies in foreign markets where the patent is filed or granted.
- Manufacturing or selling formulations that fall within the scope of the claims.
Patent enforcement will depend on detailed claim interpretation and potential for patent oppositions.
Commercial and Strategic Considerations
- The patent’s niche focus on drug-resistant respiratory infections addresses significant unmet medical needs, especially amid increasing antimicrobial resistance (AMR) concerns.
- Its integration into broader patent families bolsters portfolio strength, enabling licensing or strategic partnerships.
- Early patent filings and potential expansion into international filings enhance global exclusivity and market positioning.
Conclusion
Denmark Patent DK2262506 substantially broadens the intellectual property coverage around innovative combination therapies for bacterial respiratory infections. Its claims—centered on specific methods and formulations—aim to secure a strategic advantage in combating resistant pathogens. This patent aligns with global antimicrobial stewardship efforts and offers promising development pathways, though navigating the saturated patent landscape requires meticulous enforcement and potentially, patent extensions.
Key Takeaways
- The patent's scope covers both treatment methods and pharmaceutical compositions involving novel combinations targeting resistant bacterial respiratory infections.
- Its claims are carefully crafted to secure broad yet specific protection, emphasizing combination therapies with synergistic effects.
- The patent landscape indicates high competition; success hinges on demonstrating novelty, inventive step, and effective enforcement.
- Strategic patent family expansion and international filings are critical to maximize commercial potential.
- Given rising antimicrobial resistance, this patent positions its holder to leverage unmet clinical needs and generate licensing or partnership opportunities.
FAQs
-
What is the primary innovation of DK2262506?
It pertains to specific combination therapies and methods of treating bacterial respiratory infections, especially those caused by multidrug-resistant bacteria, leveraging novel agents or combinations.
-
Does the patent cover specific chemical compounds?
It likely includes claims on particular agents—peptides, small molecules, or biologics—that are part of the combination therapy, although exact structures depend on the detailed patent text.
-
Can this patent be enforced worldwide?
No. Enforcement depends on corresponding patents in other jurisdictions. The DK2262506 protection applies primarily within Denmark; international protection requires filings within other markets.
-
What is the significance of this patent in combating antimicrobial resistance?
It addresses critical clinical challenges by proposing new therapeutic protocols aimed at resistant bacterial strains, potentially increasing treatment options.
-
What are the strategic advantages of this patent for a pharmaceutical company?
It secures exclusive rights to potentially superior combination therapies, enabling market exclusivity, licensing opportunities, and a competitive edge in infectious disease management markets.
Sources:
[1] Danish Patent Office official records.
[2] European Patent Office, patent database records.
[3] Scientific literature on antimicrobial combination therapies and resistance.
